James A. Graham, PharmD

  • 2Articles
  • 16.4KReads1
  • 2006–2021Active
  • 13Collaborators
  • 9Citations2

About

James A. Graham, PharmD, is affiliated with Global Research & Development at Indivior Inc. in North Chesterfield, Virginia. His publications span from 2006 to 2021 and focus on clinical research in bipolar disorder and schizophrenia/schizoaffective disorders. His work includes analyses of extended-release risperidone in schizophrenia and studies on dermatologic precautions related to lamotrigine use in bipolar I disorder. He has frequently collaborated with co-authors such as Amy T. Heath and Anne C. Andorn.

Publications

JCP
Original Research

Response to Subcutaneous Injectable Monthly Risperidone (RBP-7000): PANSS Item-Level Analysis

September 21, 2021

Phase 3 study data on the efficacy of RBP-7000 for schizophrenia were examined to see if dose-response relationships exist for different items of the Positive and Negative Syndrome Scale.
, , , et al
JCP
Original Research

The Effect of Dermatologic Precautions on the Incidence of Rash With Addition of Lamotrigine in the Treatment of Bipolar I Disorder: A Randomized Trial

March 15, 2006

, , , et al

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen Now
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe